Objective To investigate the association between low-density lipoprotein receptor-related protein 5 (LRP5) variants (rs12363572 and rs4930588) and type 2 diabetes mellitus (T2DM) in Han Chinese.
Methods A total of 1842 T2DM cases (507 newly diagnosed cases and 1335 previously diagnosed cases) and 7777 controls were included in this case-control study. PCR-RFLP was conducted to detect the genotype of the two single nucleotide polymorphisms (SNPs). Odds ratios (ORs) and 95%confidence intervals (95%CIs) were calculated to describe the strength of the association by logistic regression.
Results In the study subjects, neither rs12363572 nor rs4930588 was significantly associated with T2DM, even after adjusting for relevant covariates. When stratified by body mass index (BMI), the two SNPs were also not associated with T2DM. Among the 3 common haplotypes, only haplotype TT was associated with reduced risk of T2DM (OR 0.820, 95% CI 0.732-0.919). In addition, rs12363572 was associated with BMI (P<0.001) and rs4930588 was associated with triglyceride levels (P=0.043) in 507 newly diagnosed T2DM cases but not in healthy controls.
Conclusion No LRP5 variant was found to be associated with T2DM in Han Chinese, but haplotype TT was found to be associated with T2DM.

The therapeutic effect of aerobic exercise with resistance training in elderly men with type2diabetes mellitus

Metabolically healthy obesity increase risk for hypertension,T2DM and the metabolic syndrome:A community-based cohort study

Objective:To investigate the prevalence of metabolically healthy obesity (MHO) and its relationship with incidence of metabolic syndrome (MetS),type 2 diabetes mellitus (T2DM) and hypertension in individuals in the city of Yulin.Methods:We studied 1,666 participants,aged over 18 years at baseline,with free of components of the MetS except waist criteria.Participants were divided into three groups based on body mass index (Ibm):lean/normal weight (Ibm ＜23 kg/m2),overweight (Ibm,23-24.9 kg/m2),obesity (Ibm ≥ 25 kg/m2).The cumulative incidence of MetS,T2DM and hypertension over 5.21 years among groups was assessed.Results:The prevalence of MHO was 19.5％ in the baseline population.During an average 5.21 year follow-up,the cumulative incidence of MetS,T2DM and hypertension in 1,666 participants were 16.4％,19.1％ and 3.9％,respectively.The obesity group had a significantly higher cumulative incidence of MetS (16.4％ vs.3.2％,P＜0.001),hypertension (19.1％ vs.3.7％,P＜0.001),and T2DM (3.9％ vs.1.6％,P0.001) compared to the lean/normal weight group.Each kg/m2 of Ibm carried increased risk for T2DM (19％),hypertension (11％) and MetS (13％).Conclusion:Metabolically healthy obesity individuals confer increased risk for hypertension,T2DM and the MetS than their non-obese counterparts.

α-葡萄糖苷酶抑制剂治疗2型糖尿病的系统评价

目的评价α-葡萄糖苷酶抑制剂治疗2型糖尿病患者的效果.方法检索Cochrane图书馆、MEDLINE、EMBASE、Current Contents、LILACS在研试验数据库,主题为α-葡萄糖苷酶抑制剂的综述的参考文献,并联系纳入试验的专家与实施者.近检索日期为2003年月12月(Current Contents)和2003年4月(其他数据库).纳入α-葡萄糖苷酶抑制剂单一疗法与其它干预比较,治疗2型糖尿病疗程至少12周的随机对照试验,并且试验至少包括以下结局之一:病死率、患病率、生活质量、血糖控制、血脂、胰岛素水平、体重、不良事件.两名评价者独立阅读所有摘要,评价质量并提取数据,分歧通过协商解决或由第三位评价者裁决.由一位统计学家在对提取数据输入数据库时进行检查.我们尽量联系所有作者以核实数据.结果共纳入41个试验、8 130例受试者,其中30个针对阿卡波糖,7个针对米格列醇,1个针对优格列波糖,还有3个为不同α-葡萄糖苷酶抑制剂间的比较.绝大多数研究疗程为24周,仅有2个研究超过1年.与安慰剂相比,阿卡波糖血糖控制效果更好:糖化血红蛋白-0.8%[95%CI(-0.9,-0.7)],空腹血糖-1.1 mmol/L[95%CI(-1.4,-0.9)],负荷血糖-2.3 mmol/L[95%CI(-2.7,-1.9)],阿卡波糖对糖化血红蛋白的作用呈非剂量依赖.我们发现其可降低负荷胰岛素,但对血脂和体重未见临床相关的作用.不良反应主要来自胃肠道且与剂量相关.相对于磺脲,阿卡波糖将空腹和负荷胰岛素水平分别降低至-24.8 pmol/L[95%CI(-43.3,-6.3)]和-133.2 pmol/L[95%CI(-184.5,-81.8)],但阿卡波糖引起的不良反应更多.结论关于α-葡萄糖苷酶抑制剂是否影响2型糖尿病患者的病死率和患病率仍不清楚.相反,其对血糖控制或胰岛素水平作用明显,对血脂和体重的作用差异无统计学意义.α-葡萄糖苷酶抑制剂更长疗程的效果仍不确定.阿卡波糖剂量超过50 mg(TID)时不能进一步影响糖化血红蛋白水平,不良反应反而更多,与磺脲相比,α-葡萄糖苷酶抑制剂降低了空腹和负荷胰岛素水平,但在血糖控制和不良反应方面存在不利影响.